Disclosures. G. Alangaden, T2 Biosystems: Speaker's Bureau, Educational grant and Speaker honorarium. Background. Β-D glucan (BDG) assay is a noninvasive test for presumptive diagnosis of invasive fungal infections (IFI). The utility of BDG assay and cut off values for positive, intermediate or negative test has been primarily studied in patients with hematological malignancies. However, the role of BDG in solid-organ transplant (SOT) recipients is not well described. The aim of this study was to evaluate the utility of serum BDG assay for IFI diagnosis in SOT recipients.
Utility of Serum Β-D Glucan
Methods. We retrospectively reviewed 200 patients who underwent SOT at Mayo Clinic and had BDG assay done for suspected IFI between January 1, 2013 and April 1, 2018. IFI cases were classified as proven, probable, and possible using EORTC/MSG criteria. Cases where BDG assay was used for treatment response follow-up or where results were inconclusive were excluded. BDG assay was performed at Viracor Eurofins Clinical Diagnostics lab. For the purpose of this study, a value of ≥80 pg/mL was considered positive and <80 pg/mL (intermediate or negative) was considered negative.
Results. A total of 117 tests from 104 patients met study inclusion criteria. The mean patient age was 56.2 years and 71 (60.7%) were male. Type of SOT included kidney (64), liver (30), heart (26), pancreas (6), and lung (6). BDG assay was positive in seven out of 10 invasive aspergillosis, two out of 3 invasive candidiasis, three out of four pulmonary coccidioidomycosis, and one Pneumocystis jirovecii pneumonia (Table 1) . Overall, BDG assay was positive in 72.7% of cases (16/22) where a BDG containing organism was the etiology of invasive infection (sensitivity). It was false-positive in seven cases where a BDG containing organism was not identified. Overall specificity of the assay was 92.6% (Table 2) .
Conclusion. BDG assay is a useful adjunctive diagnostic aid for distinguishing IFI cases from those without IFI in SOT recipients. Background. The identification of yeast traditionally entails macroscopic/microscopic findings and biochemical testing. Recently, MALDI TOF MS has replaced traditional methods for identification as a proposed new standard. We performed identification of previously unidentifiable yeasts from a collection in the United States.
Methods. The Mycoses Study Group (MSG) collected 2,947 Candida isolates from 1,911 patients as part of two U.S. studies between 1995 and 1999. The identification of the isolates was done in 2002 using API 20 c aux with supplemented standard mycological and biochemical test (corn meal agar, germ tube and the Murex ID system). Ninety-four isolates could not be identified at that time. For this study, the isolates were defrosted, plated on Sabureau Dextrose agar, and incubated at 30°C for 48 hours. We then sub-cultured again in Blood Agar. Isolates when then tested by MALDI TOF MS following the methodology for the Bruker MALDI biotyper.
Results. In the first attempt, 65/94 (69%) isolates were identified. The remaining 29 samples were re-tested with a yield of 21/29 (72.4%) identified isolates. The remaining isolates had to be identified with another round of MALDI TOF and further biochemical testing. The table below shows the final identification of the isolates.
Conclusion. MALDI TOF MS is rapidly becoming a reference method for yeast identification. However, in a historical collection of yeast that could not be identified by conventional biochemical methods, it took up to three rounds of MALDI TOF MS with a yield of ~70% per round, and additional biochemical testing, for identification of all isolates. Continuing validation of MALDI TOF MS for identification of difficult yeast isolates is warranted. 
